Patent ID: 9447469
Filing Date: 2016-09-20
CPC Classification: A61K,C12Q

Claim Text:
1. A method for administering a VEGF-based therapy to a subject, the method comprising administering a VEGF-based therapy selected from bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, and thiazolidinedione to a subject known to have an allelic variant selected from the group consisting of: i. rs6921438, wherein a guanine residue is present at base 323 of SEQ ID No.1 at one or both alleles, ii. rs4416670, wherein a thymine residue is present at base 221 of SEQ ID Not at one or both alleles, iii. rs6993770, wherein a thymine residue is absent at base 235 of SEQ ID No.3 at one or both alleles, and iv. rs10738760, wherein a guanine residue is present at 201 of SEQ ID No.4 at one or both alleles.